These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26563428)

  • 1. Smart materials: in situ gel-forming systems for nasal delivery.
    Karavasili C; Fatouros DG
    Drug Discov Today; 2016 Jan; 21(1):157-166. PubMed ID: 26563428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucoadhesive in situ nasal gelling drug delivery systems for modulated drug delivery.
    Singh RM; Kumar A; Pathak K
    Expert Opin Drug Deliv; 2013 Jan; 10(1):115-30. PubMed ID: 23199072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chitosan-Based In Situ Gels for Ocular Delivery of Therapeutics: A State-of-the-Art Review.
    Irimia T; Dinu-Pîrvu CE; Ghica MV; Lupuleasa D; Muntean DL; Udeanu DI; Popa L
    Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30304825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo evaluation of cubosomal in situ nasal gel containing resveratrol for brain targeting.
    Ahirrao M; Shrotriya S
    Drug Dev Ind Pharm; 2017 Oct; 43(10):1686-1693. PubMed ID: 28574732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral liquid in situ gelling methylcellulose/alginate formulations for sustained drug delivery to dysphagic patients.
    Shimoyama T; Itoh K; Kobayashi M; Miyazaki S; D'Emanuele A; Attwood D
    Drug Dev Ind Pharm; 2012 Aug; 38(8):952-60. PubMed ID: 22283456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery.
    Agrawal M; Saraf S; Saraf S; Dubey SK; Puri A; Gupta U; Kesharwani P; Ravichandiran V; Kumar P; Naidu VGM; Murty US; Ajazuddin ; Alexander A
    J Control Release; 2020 Nov; 327():235-265. PubMed ID: 32739524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Evaluation of a Novel Intranasal Spray for the Delivery of Amantadine.
    Lungare S; Bowen J; Badhan R
    J Pharm Sci; 2016 Mar; 105(3):1209-20. PubMed ID: 26886345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ gelling polymers in ocular drug delivery systems: a review.
    Mundada AS; Avari JG
    Crit Rev Ther Drug Carrier Syst; 2009; 26(1):85-118. PubMed ID: 19496748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept.
    Patel N; Thakkar V; Metalia V; Baldaniya L; Gandhi T; Gohel M
    Drug Dev Ind Pharm; 2016 Sep; 42(9):1406-23. PubMed ID: 26716613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancement in stimuli triggered in situ gelling delivery for local and systemic route.
    Ajazuddin ; Alexander A; Khan J; Giri TK; Tripathi DK; Saraf S; Saraf S
    Expert Opin Drug Deliv; 2012 Dec; 9(12):1573-92. PubMed ID: 23075325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized formulation for topical administration of clotrimazole using Pemulen polymeric emulsifier.
    Shahin M; Hady SA; Hammad M; Mortada N
    Drug Dev Ind Pharm; 2011 May; 37(5):559-68. PubMed ID: 21128701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising Polymeric Drug Carriers for Local Delivery: The Case of
    Okur NÜ; Yağcılar AP; Siafaka PI
    Curr Drug Deliv; 2020; 17(8):675-693. PubMed ID: 32510291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel.
    Gratieri T; Gelfuso GM; de Freitas O; Rocha EM; Lopez RF
    Eur J Pharm Biopharm; 2011 Oct; 79(2):320-7. PubMed ID: 21641994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations.
    Escobar-Chávez JJ; López-Cervantes M; Naïk A; Kalia YN; Quintanar-Guerrero D; Ganem-Quintanar A
    J Pharm Pharm Sci; 2006; 9(3):339-58. PubMed ID: 17207417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Site-specific drug delivery systems. III. Nasal drug delivery].
    Szente V; Zelkó R
    Acta Pharm Hung; 2008; 78(2):87-90. PubMed ID: 18807389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ gel-forming system: an attractive alternative for nasal drug delivery.
    Wang X; Liu G; Ma J; Guo S; Gao L; Jia Y; Li X; Zhang Q
    Crit Rev Ther Drug Carrier Syst; 2013; 30(5):411-34. PubMed ID: 24099327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimuli-Responsive Systems with Diverse Drug Delivery and Biomedical Applications: Recent Updates and Mechanistic Pathways.
    Singh B; Khurana RK; Garg B; Saini S; Kaur R
    Crit Rev Ther Drug Carrier Syst; 2017; 34(3):209-255. PubMed ID: 28845760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal-nanotechnology: revolution for efficient therapeutics delivery.
    Kumar A; Pandey AN; Jain SK
    Drug Deliv; 2016; 23(3):681-93. PubMed ID: 24901207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Situ Forming Depot as Sustained-Release Drug Delivery Systems.
    Kanwar N; Sinha VR
    Crit Rev Ther Drug Carrier Syst; 2019; 36(2):93-136. PubMed ID: 30806210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and evaluation of gel formulations for oral sustained delivery to dysphagic patients.
    Miyazaki S; Takahashi A; Itoh K; Ishitani M; Dairaku M; Togashi M; Mikami R; Attwood D
    Drug Dev Ind Pharm; 2009 Jul; 35(7):780-7. PubMed ID: 19337871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.